HONZ(SZ:300086) Xin Lang Cai Jing·2026-01-26 08:02Core Viewpoint - Kangzhi Pharmaceutical (300086.SZ) has been selected for the centralized procurement of its product, Levocetirizine Hydrochloride Granules, in Hebei Province, which is expected to enhance market sales and share, positively impacting the company's long-term development [1] Group 1: Product and Procurement Details - The selected product specification is 2.5mg, indicated for conditions such as urticaria, allergic rhinitis, eczema, dermatitis, and pruritus [1] - The procurement results will be officially implemented on March 1, 2026, with an annual signing during the procurement cycle [1] Group 2: Market Impact and Uncertainties - The selection is anticipated to expand the market sales of the selected product and increase market share [1] - However, the related procurement contract has not yet been signed, leading to uncertainties regarding the actual progress and its impact on the company's future performance [1]